2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Non-Biological Therapies, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Genomics, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, CLL, B Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

2147 Phase II comparative study of anti-pneumococcal vaccine strategies in patients with chronic lymphocytic leukemia

Seema Ali Bhat, MD, Reham Ibrahim, MBBCh2, Ying Huang, MA, MS3, Lillian Dweik4, Aseel Alsouqi, MD5, Amneet Kaur Bajwa, MD6, Cara Grantier, CNP7, Michael Grever, MD8, Swetha Hinton, CNP9, Corinne Hoffman, MS, NP10, Adam Kittai, MD11, Mollie Moran, CNP12, Sarah Mustric, CNP13, Mark Reid, CNP14, Kerry A. Rogers, MD15, Jennifer A. Woyach, MD16
1 The Ohio State University, Columbus, Ohio, United States
2 The Ohio State University, Columbus, Ohio, United States
3 The Ohio State University, Columbus, Ohio, United States
4 The Ohio State University, Columbus, Ohio, United States
5 The Ohio State University, Columbus, Ohio, United States
6 The Ohio State University, Columbus, Ohio, United States
7 The Ohio State University, Columbus, Ohio, United States
8 The Ohio State University, Columbus, Ohio, United States
9 The Ohio State University, Columbus, Ohio, United States
10 The Ohio State University, Columbus, Ohio, United States
11 New York University, New York, New York, United States
12 The Ohio State University, Columbus, Ohio, United States
13 The Ohio State University, Columbus, Ohio, United States
14 The Ohio State University, Columbus, Ohio, United States
15 The Ohio State University, Columbus, Ohio, United States
16 The Ohio State University, Columbus, Ohio, United States

Background and Significance: 
Standard vaccination recommendations do not exist for patients with chronic lymphocytic leukemia (CLL) and vaccination schedules are based on recommendations in immunocompromised patients. In 2021, Pneumococcal conjugate vaccine (PCV)20 was recommended as pneumococcal vaccination option for all adults aged ≥65 and for adults aged 19-64 with certain medical conditions or other risk factors for pneumococcal disease including immunocompromised state. Immunization with Pneumococcal polysaccharide vaccine (PSV)23 is no longer recommended following PCV20. Patients with CLL were excluded from the trial that led to the approval of PCV20. Also, the benefit of combining PCV20 and PSV23 is currently unknown in patients with CLL. Given the impaired vaccine responses observed in CLL and the persistent risk of invasive pneumococcal disease, sequential vaccination with PCV20 followed by PPSV23 may provide broader serotype coverage and improve overall protection compared with PCV20 alone. Since vaccine responses in general are suboptimal in patients with CLL, we hypothesized that PCV20 alone may not be sufficient to elicit adequate immunogenicity because broader serotype coverage alone is unlikely to overcome the disease-related defects in humoral and cellular immunity that impair vaccine responses in patients with CLL. Additional immunization with PSV23 at 8 weeks or as additional yearly immunization for 5 years may result in maintaining higher protective titers in our patients. We designed a prospective randomized 3-arm study comparing three anti-pneumococcal vaccination strategies in patients with CLL.

Study Design and Methods:
This single center prospective, randomized phase 2 study, NCT05417165, is comparing novel anti-pneumococcal vaccination strategies with the standard strategy of single vaccine dose of PCV20 in patients with CLL. The study is currently enrolling patients at The Ohio State University in Columbus, OH. Eligible patients must have untreated CLL or small lymphocytic lymphoma. Patients who have previously received pneumococcal vaccine within the preceding 12 months or who have received intravenous immunoglobulins within the past 3 months are excluded. Patients will be randomized in 1:1:1 ratio to 3 arms, where Arm A will receive only one standard dose of PCV20, Arm B will receive PSV23 8 weeks after the initial dose of PCV20, and Arm C will receive PSV23 8 weeks after the initial dose of PCV20 followed by 5 yearly booster doses of PSV23. Randomization will be stratified based on IgG levels.  The primary endpoint is the proportion of patients with anti-pneumococcal immunogenicity (serotype titers) measured by ELISA and defined as achieving 2-fold increase from baseline. This proportion will be compared between Arm A and Arm B at 12 weeks. We hypothesize that the vaccine success rate will be 20% in Arm A versus 60% in Arm B at week 12. With 24 evaluable patients in each arm, there is at least 90% power to detect an increase in vaccine success rate from 20% to 60% and constraining the one-sided type I error rate to 5%.

Secondary endpoint is the effect of yearly booster vaccination with PSV23 in arm C. A secondary comparison will be conducted between Arm B and Arm C for the proportion of vaccine success at year 2. With 24 patients in each arm and one-sided type I error rate of 5%, at least 81% power can be achieved to detect a 35% increase in the vaccine success rate, assuming pneumococcal immunogenicity could be maintained in 25% to 50% of patients in Arm B by year 2. The overall sample size of three arms combined is 72 patients. Power was calculated using a one-sided z-test for the difference in two proportions with pooled variance (PASS v13; NCSS, LLC).

Safety will be characterized by the number of patients with local and/or systemic reactions within 10 days and 7 days after vaccination, respectively; number of patients with other adverse events within 1 month after vaccination and the number of pneumococcal infections per patient within 5 years.   

Study Progress:
To date, 64 patients have been accrued to the study; 21 in arm A, 22 in arm B and 20 in arm C. One patient withdrew consent before randomization. The study is actively recruiting. The results are expected to fill an information gap in supportive care for patients with CLL with the potential to establish evidence-based pneumococcal vaccination strategies for patients with CLL and directly inform future vaccination guidelines.

Seema Ali Bhat, MD: AstraZeneca - Research Funding; Genentech - Consultancy (Includes expert testimony); Pharmacyclics - Consultancy (Includes expert testimony); BeOne - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony)